![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00426608 |
A study to investigate the effects GSK561679 on part of the body's system that controls the balance of many of the hormones (including cortisol).
Condition | Intervention | Phase |
Healthy Volunteer |
Drug: Single dose of metyrapone Drug: Single dose of alprazolam Drug: Single dose of placebo Drug: Single dose of GSK561679 |
Phase I |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover Study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone With a Single Dose of GSK561679 or Alprazolam in Healthy Volunteers |
Enrollment: | 20 |
Study Start Date: | October 2006 |
Study Completion Date: | January 2007 |
Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion:
Exclusion:
United Kingdom | |||||
GSK Clinical Trials Call Center | |||||
Cambridge, United Kingdom, CB2 2GG |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MBChB, DA(SA), Dip Pharm Med | GlaxoSmithKline |
Study ID Numbers: | CRS105511 |
First Received: | January 23, 2007 |
Last Updated: | April 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00426608 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|
|
|
![]() |